Novel therapies are changing treatment paradigms in metastatic prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair...

Descripción completa

Detalles Bibliográficos
Autores principales: Powers, Eric, Karachaliou, Georgia Sofia, Kao, Chester, Harrison, Michael R., Hoimes, Christopher J., George, Daniel J., Armstrong, Andrew J., Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594418/
https://www.ncbi.nlm.nih.gov/pubmed/33115529
http://dx.doi.org/10.1186/s13045-020-00978-z
_version_ 1783601630902484992
author Powers, Eric
Karachaliou, Georgia Sofia
Kao, Chester
Harrison, Michael R.
Hoimes, Christopher J.
George, Daniel J.
Armstrong, Andrew J.
Zhang, Tian
author_facet Powers, Eric
Karachaliou, Georgia Sofia
Kao, Chester
Harrison, Michael R.
Hoimes, Christopher J.
George, Daniel J.
Armstrong, Andrew J.
Zhang, Tian
author_sort Powers, Eric
collection PubMed
description Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials.
format Online
Article
Text
id pubmed-7594418
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75944182020-10-30 Novel therapies are changing treatment paradigms in metastatic prostate cancer Powers, Eric Karachaliou, Georgia Sofia Kao, Chester Harrison, Michael R. Hoimes, Christopher J. George, Daniel J. Armstrong, Andrew J. Zhang, Tian J Hematol Oncol Review Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials. BioMed Central 2020-10-28 /pmc/articles/PMC7594418/ /pubmed/33115529 http://dx.doi.org/10.1186/s13045-020-00978-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Powers, Eric
Karachaliou, Georgia Sofia
Kao, Chester
Harrison, Michael R.
Hoimes, Christopher J.
George, Daniel J.
Armstrong, Andrew J.
Zhang, Tian
Novel therapies are changing treatment paradigms in metastatic prostate cancer
title Novel therapies are changing treatment paradigms in metastatic prostate cancer
title_full Novel therapies are changing treatment paradigms in metastatic prostate cancer
title_fullStr Novel therapies are changing treatment paradigms in metastatic prostate cancer
title_full_unstemmed Novel therapies are changing treatment paradigms in metastatic prostate cancer
title_short Novel therapies are changing treatment paradigms in metastatic prostate cancer
title_sort novel therapies are changing treatment paradigms in metastatic prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594418/
https://www.ncbi.nlm.nih.gov/pubmed/33115529
http://dx.doi.org/10.1186/s13045-020-00978-z
work_keys_str_mv AT powerseric noveltherapiesarechangingtreatmentparadigmsinmetastaticprostatecancer
AT karachaliougeorgiasofia noveltherapiesarechangingtreatmentparadigmsinmetastaticprostatecancer
AT kaochester noveltherapiesarechangingtreatmentparadigmsinmetastaticprostatecancer
AT harrisonmichaelr noveltherapiesarechangingtreatmentparadigmsinmetastaticprostatecancer
AT hoimeschristopherj noveltherapiesarechangingtreatmentparadigmsinmetastaticprostatecancer
AT georgedanielj noveltherapiesarechangingtreatmentparadigmsinmetastaticprostatecancer
AT armstrongandrewj noveltherapiesarechangingtreatmentparadigmsinmetastaticprostatecancer
AT zhangtian noveltherapiesarechangingtreatmentparadigmsinmetastaticprostatecancer

Ejemplares similares